This page contains recent news articles, when available, and an overview of but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Background information on

Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative ...  -  Mar 17, 2008
Earthtimes,Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) that affect over

Upbeat outlook on life  -  Feb 29, 2008
Journal Times,Myeloproliferative disorders is the general term for a closely related group of progressive blood cancers like the one with which Blocks was diagnosed.

Seattle Genetics Initiates SGN-33 Clinical Trial in Combination ...  -  Mar 20, 2008
Earthtimes,...that targets the CD33 antigen, which is expressed on a number of hematologic malignancies, including AML, MDS and several myeloproliferative disorders.

New Genetic Test Detects Rare, Deadly, Difficult-to-Diagnose Blood ...  -  Mar 7, 2008
PR Web (press release),The JAK2 mutation is also found in approximately half of all patients who are diagnosed with other similar myeloproliferative disorders, such as Essential

Seattle Genetics initiates MDS combination therapy trial  -  Mar 21, 2008
Trading Markets (press release),...which is expressed on a number of hematologic malignancies, including acute myeloid leukemia, MDS and several myeloproliferative disorders.

Morgan named to state council  -  Feb 8, 2008
Stuttgart Daily Leader,...that are treatable with cord blood, including stem cell disorders, acute and chronic forms of leukemia, myeloproliferative disorders among others.

JAK2V617F mutation screening in WHO 2008 criteria  -  Jan 22, 2008
Laboratory Talk,...new information on the molecular pathogenesis of BCR - ABL negative myeloproliferative disorders including the screening for JAK2V617F mutation.

Cytopia's JAK2 inhibitor shows potent activity  -  Jan 29, 2008
Trading Markets (press release),...its lead JAK2 inhibitor compound, CYT387, had demonstrated potent activity in cells isolated from patients with myeloproliferative disorders (MPDs).

Incyte To Webcast A Discussion Of Its JAK Inhibitor, INCB18424 ...  -  Dec 5, 2007
WELT ONLINE,The discussion will feature Srdan Verstovsek, MD, Ph.D., Associate Professor Leukemia Department, Myeloproliferative Disorders and Program Leader,

S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic ...  -  Dec 10, 2007
Earthtimes,..."We are pleased to announce data for the first time on our JAK2 inhibitor, SB1518, and its potential treatment of myeloproliferative disorders,

Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel ...  -  Dec 10, 2007
CNNMoney.comXL019 is a highly selective inhibitor of JAK2 that may have the potential to provide important benefit for patients with myeloproliferative disorders and

Data Presented At The American Society Of Hematology 49th Meeting ...  -  Dec 16, 2007
PR-USA.net (press release),Srdan Verstovsek, MD, PhD., Associate Professor Leukemia Department, Myeloproliferative Disorders Program Leader, University of Texas MD Anderson Cancer

Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation ...  -  Dec 7, 2007
Reuters...analysis provides the hematologist/oncologist with a new diagnostic tool in the identification and management of myeloproliferative disorders, or MPD,

Ipsogen launches the first quantitative mutation kit  -  Dec 14, 2007
Medical Laboratory World,Traditionally, the diagnosis of MyeloProliferative Disorders (MPDs) is based on clinical, bone marrow, histological, immunophenotypic and cytogenetic

49th Annual Meeting of the American Society of Hematology Will ...  -  Dec 5, 2007
Earthtimes,Lecture on Saturday, December 8, from 12:30 pm to 1:30 pm Dr. Skoda's lecture will focus on the molecular basis of myeloproliferative disorders (MPDs).

A Super(Gen) Play on Cancer Biotech Consolidation  -  Dec 16, 2007
Seeking Alpha,Also in pre-clinical development is a JAK2 kinase inhibitor, which has demonstrated activity in solid tumors and myeloproliferative disorders.

IPSOGEN To Undertake Pilot Study On JAK2 Cancer Biomarker With ...  -  Dec 3, 2007
Medical News Today (press release),...solution of products and services in order to assist pharmaceutical companies in the development of JAK2 inhibitors in myeloproliferative disorders.

ipsogen launches the first quantitative jak2 v617f mutation kit  -  Nov 20, 2007
Medical News Today (press release),...a research tool intended for the accurate quantification of jak2 v617f mutation*. traditionally, the diagnosis of myeloproliferative disorders (mpds) is

biotech wizards load up on two biotech stocks; insiders bullish on ...  -  Nov 15, 2007
IndiaStockMarket.com,...sometimes these enzymes get out of control and pay a key role in the development of inflammatory diseases, â€œmyeloproliferative disordersâ€? in which the

seattle genetics initiates phase iib clinical trial of sgn-33 in ...  -  Nov 9, 2007
Business Wire (press release),...which is expressed on a number of hematologic malignancies, including aml, mds and several myeloproliferative disorders. preliminary data reported from

exelixis q3 2007 earnings call transcript  -  Nov 5, 2007
Seeking Alpha,...advanced inhibitors of jak2. this target is a driver of aberrant proliferation of blood cells in many patients with myeloproliferative disorders and may

Incyte Rises on Clinical Trial Data  -  Sep 26, 2007
Forbes,..."We are encouraged by the progress of the program thus far and believe at this time that the myeloproliferative disorders indication could represent both

Incyte reports positive proof-of-concept results for INCB18424 ...  -  Sep 25, 2007
Reuters...potentially, cancers, beyond the myeloproliferative disorders, which means we could have additional proof-of-concept data to report throughout 2008.

Negative-Pressure Wound Therapy and External Fixation for ...  -  Sep 27, 2007
Journal of the American Podiatric Medical Association (subscription)5 A higher incidence of hematoma formation is seen in patients with myeloproliferative disorders, polycythemia vera, and coagulation defects.

Incyte Reports Positive Proof-Of-Concept Results For INCB18424 And ...  -  Sep 25, 2007
RTT News,...cancers, beyond the myeloproliferative disorders, from which the company expects additional proof-of-concept data to report throughout 2008.

Warnex announces an exclusive licence with Ipsogen to market a ...  -  Aug 14, 2007
Canada NewsWire (press release),Finding the JAK2 mutation is a major step forward in diagnosing myeloproliferative disorders for the wellbeing of all Canadians.

Myeloproliferative Disorders (Hematologic Malignancies)  -  Jul 17, 2007
Journal of American Medical Association (subscription),First identified and named by William Dameshek in 1951, myeloproliferative disorders have become "landmarks in the history of malignant disease . . . on

Aegera Therapeutics Acquires Clinical Stage Oncology Company and ...  -  Aug 8, 2007
CNW Telbec (CommuniquÃ©s de presse),...a small molecule tyrosine kinase inhibitor in Phase 1 clinical trials for acute myelogenous leukemia and other myeloproliferative disorders.

Running: Lisa Smith-Batchen takes on the 300-mile Badwater Double ...  -  Jul 26, 2007
RunnersWeb,MPDs, the common term for myeloproliferative disorders, are progressive blood cancers that can strike anyone at any age, and for which there is no known

Wintrobeâ€™s Atlas of Clinical Hematology  -  Jun 19, 2007
Journal of American Medical Association (subscription),The acute leukemias are discussed in terms of 12 subtypes and the chronic myeloproliferative disorders in 10 subtypes. The lymphoproliferative disorders are

TODAY'S MOST POPULAR  -  Jun 13, 2007
Wall Street JournalTHE CMPD Education Foundation, for myeloproliferative disorders, is run by Joyce Niblack at mpdinfo.org. Yesterday's Informed Patient column incorrectly

Of Online Patient Groups  -  Jun 12, 2007
Wall Street JournalLater, Ms. Niblack mustered 1179 participants from 30 countries for a Mayo Clinic-led study of how the cancers, known as myeloproliferative disorders,

New Strategies for Pulmonary Arterial Hypertension: Evaluation and ...  -  Apr 23, 2007
Medscape (subscription)...myeloproliferative disorders, splenectomy); and PAH associated with significant venous or capillary involvement (pulmonary veno-occlusive disease,

SGX Pharmaceuticals Updates Analysts and Investors on Oncology ...  -  Feb 15, 2007
Earthtimes.orgJAK2 is implicated in various myeloproliferative disorders estimated to affect 80000-100000 people in the US Compounds from these lead series have shown

Incyte Reviews Recent Progress in Multiple Programs; Announces ...  -  Feb 15, 2007
Business Wire (press release),For our JAK2 program, that we believe may have utility in chronic inflammatory conditions, myeloproliferative disorders, and certain other cancers,

SGX Pharmaceuticals Updates Analysts and Investors on Oncology ...  -  Feb 16, 2007
PharmaLive.com (press release),JAK2 is implicated in various myeloproliferative disorders. disorders. Oral bioavailability has also been demonstrated. SGX is

JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic ...  -  Jan 31, 2007
New England Journal of Medicine (subscription),However, the molecular basis of these myeloproliferative disorders in patients without the V617F mutation is unclear. Methods We searched for new mutations

Dacogenâ„¢ Has Significant Activity in Chronic Myelomonocytic Leukemia  -  Feb 9, 2007
Cancer Consultants (press release),...(CMML) is considered to be a separate clinical entity, but possesses features of both myelodysplastic syndromes (MDS) and myeloproliferative disorders.

Cytopia books a 71.1% reduction in 1H operating loss  -  Feb 8, 2007
egoli.com.au,...â€œThere are multiple JAK2 opportunities with a core cancer focus and also applicability in myeloproliferative disorders and cardiovascular diseases,â€? the

Drug Shown To Be Clinically Active Against Multiple Target ...  -  Dec 24, 2006
Haber SaÄŸlÄ±k,In addition, the trial showed the first activity against the JAK-2 mutation found in myeloproliferative disorders (MPD), a group of blood diseases that can

MD Anderson phase 1/2 study shows multi-kinase inhibitor active ...  -  Jan 4, 2007
Therapeutics Daily (subscription) (press release),...a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders,

... Go to the Article  -  Jan 4, 2007
CancerWise...treatment for rare but dangerous mutations in acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML) and myeloproliferative disorders (MPD).

Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th ...  -  Jan 8, 2007
CNW Telbec (CommuniquÃ©s de presse),Vertex and Merck reported data for VX- 680 in patients with treatment-resistant forms of advanced leukemias and myeloproliferative disorders.

Merck and Vertex Announce Phase I Results for Investigational ...  -  Dec 11, 2006
CNW Telbec (CommuniquÃ©s de presse),Phase I Trial >> The Phase I dose escalation clinical trial evaluated 44 adult patients with advanced leukemias and myeloproliferative disorders who were

Drug Shown To Be Clinically Active Against Multiple Target ...  -  Dec 20, 2006
Science Daily (press release)In addition, the trial showed the first activity against the JAK-2 mutation found in myeloproliferative disorders (MPD), a group of blood diseases that can

Merck and Vertex Announce Phase I Results for Investigational ...  -  Dec 11, 2006
Drug Newswire (press release),The Phase I dose escalation clinical trial evaluated 44 adult patients with advanced leukemias and myeloproliferative disorders who were treated with

Merck, Vertex leukemia drug shows promise in trial  -  Dec 11, 2006
ReutersMerck's drug also showed activity against a genetic mutation sometimes present in myeloproliferative disorders, or MPD, a group of blood diseases that can

AUDIO SUMMARY  -  Dec 6, 2006
New England Journal of Medicine (subscription),...and imatinib mesylate and the heart; review articles on peginterferon and ribavirin for chronic hepatitis C and on the myeloproliferative disorders;

Five-year Study By OHSU Cancer Institute Shows Gleevec's Excellent ...  -  Dec 14, 2006
Medical News Today (press release),...dermatofibrosarcoma protuberans, Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myeloproliferative disorders,

MD Anderson scientists report leukemia drug progress  -  13 Dec 2006
Houston Business Journal,II trials show that it is clinically active against multiple target mutations in two types of leukemia and so-called myeloproliferative disorders, and produces ...

Merck, Vertex leukemia drug shows promise in trial  -  Dec 11, 2006
ReutersMerck's drug also showed activity against a genetic mutation sometimes present in myeloproliferative disorders, or MPD, a group of blood diseases that can ...

Gleevec's excellent survival rate  -  Dec 8, 2006
HULIQ,...protuberans, Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and ...

AUDIO SUMMARY  -  Dec 6, 2006
New England Journal of Medicine (subscription),...and imatinib mesylate and the heart; review articles on peginterferon and ribavirin for chronic hepatitis C and on the myeloproliferative disorders; a clinical ...

Journal of the American Podiatric Medical Association  -  Nov 17, 2006
Journal of the American Podiatric Medical Association (subscription)Cutaneous ulceration secondary to chemotherapeutic hydroxyurea is an uncommon complication of treatment for myeloproliferative disorders and other ...

New Family Support Group To Start  -  Nov 14, 2006
Devine Media,...members and caregivers whose lives have been touched by a blood cancer; leukemia, lymphoma, myeloma, Hodgkinâ€™s disease, MDS and myeloproliferative disorders. ...

Search the web for more resources on

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.